Add-on effects of a low-dose aripiprazole in resolving hyperprolactinemia induced by risperidone or paliperidone

Psychiatry Research

Volumn 237, Issue , 2016, Pages 83-89

  Qiao, Ying ^a   Yang, Fuzhong ^a   Li, Chunbo ^a   Guo, Qian ^a   Wen, Hui ^a   Zhu, Suoyu ^b   Ouyang, Qiong ^c   Shen, Weidi ^a   Sheng, Jianhua ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Aripiprazole; Paliperidone; Prolactin; Randomized controlled study; Risperidone; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ESTRADIOL; PALIPERIDONE; PROLACTIN; RISPERIDONE; NEUROLEPTIC AGENT;

ADJUVANT THERAPY; ADULT; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SAFETY; EVENING DOSAGE; EXTRAPYRAMIDAL SYNDROME; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MORNING DOSAGE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; PALIPERIDONE PALMITATE; PROLACTIN; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84959190047     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2015.12.033     Document Type: Article

References (53)

1. Bancroft J. Endocrinology of sexual function. Clin. Obstet. Gynaecol. 1980, 7(2):253-281.
2. Bergemann N., Mundt C., Parzer P., Jannakos I., Nagl I., Salbach B., Klinga K., Runnebaum B., Resch F. Plasma concentrations of estradiol in women suffering from schizophrenia treated with conventional versus atypical antipsychotics. Schizophr. Res. 2005, 73(2-3):357-366.
3. Bowles T.M., Levin G.M. Aripiprazole: a new atypical antipsychotic drug. Ann. Pharmacother. 2003, 37(5):687-694.
4. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 2002, 302(1):381-389.
5. Byerly M., Suppes T., Tran Q.V., Baker R.A. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J. Clin. Psychopharmacol. 2007, 27(6):639-661.
6. Byerly M.J., Marcus R.N., Tran Q.V., Eudicone J.M., Whitehead R., Baker R.A. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr. Res. 2009, 107(2-3):218-222.
7. Canuso C.M., Goldstein J.M., Wojcik J., Dawson R., Brandman D., Klibanski A., Schildkraut J.J., Green A.I. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res. 2002, 111(1):11-20.
8. Centorrino F., Goren J.L., Hennen J., Salvatore P., Kelleher J.P., Baldessarini R.J. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits. Am. J. Psychiatry 2004, 161(4):700-706.
9. Chen C.K., Huang Y.S., Ree S.C., Hsiao C.C. Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(8):1495-1499.
10. Chen J.X., Su Y.A., Bian Q.T., Wei L.H., Zhang R.Z., Liu Y.H., Correll C., Soares J.C., Yang F.D., Wang S.L., Zhang X.Y. Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology 2015, 58:130-140.
11. Chen J.X., Su Y.A., Wang S.L., Bian Q.T., Liu Y.H., Wang N., Yang F.D., Haile C., Kosten T.R., Zhang X.Y. Aripiprazole treatment of risperidone-induced hyperprolactinemia. J. Clin. Psychiatry 2009, 70(7):1058-1059.
12. Clevenger C.V., Furth P.A., Hankinson S.E., Schuler L.A. The role of prolactin in mammary carcinoma. Endocr. Rev. 2003, 24(1):1-27.
13. Duggal H.S. Aripirazole-olanzapine combination for treatment of schizophrenia. Can. J. Psychiatry 2004, 49(2):151.
14. Faries D., Ascher-Svanum H., Zhu B., Correll C., Kane J. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005, 5:26.
15. Fleischhacker W.W., Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int. J. Neuropsychopharmacol. 2012, 17(7):1083-1093.
16. Ganesan S., Taylor R., Rabheru K., Forbes I., Dumontet J., Procyshyn R.M. Antipsychotic polypharmacy does not increase the risk for side effects. Schizophr. Res. 2008, 98(1-3):323-324.
17. Glick I.D., Duggal V., Hodulik C. Aripiprazole as a dopamine partial agonist: positive and negative effects. J. Clin. Psychopharmacol. 2006, 26(1):101-103.
18. Goffin V., Binart N., Touraine P., Kelly P.A. Prolactin: the new biology of an old hormone. Annu. Rev. Physiol. 2002, 64:47-67.
19. Goodwin G., Fleischhacker W., Arango C., Baumann P., Davidson M., de Hert M., Falkai P., Kapur S., Leucht S., Licht R., Naber D., O'Keane V., Papakostas G., Vieta E., Zohar J. Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur. Neuropsychopharmacol. 2009, 19(7):520-532.
20. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 2004, 64(20):2291-2314.
21. Halbreich U., Kahn L.S. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J. Psychiatr. Pract. 2003, 9(5):344-353.
22. Holt R.I., Peveler R.C. Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management. Clin. Endocrinol. 2010, 74(2):141-147.
23. Howes O.D., Wheeler M.J., Pilowsky L.S., Landau S., Murray R.M., Smith S. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J. Clin. Psychiatry 2007, 68(3):361-367.
24. Hui Y., Qi D.L. The progress of research on hyperprolactinemia. J. Int. Reprod. Health/Fam. Plan. 2004, 23(3):147-150.
25. Johnsen E., Kroken R.A., Abaza M., Olberg H., Jorgensen H.A. Antipsychotic-induced hyperprolactinemia: a cross-sectional survey. J. Clin. Psychopharmacol. 2008, 28(6):686-690.
26. Kane J.M., Correll C.U., Goff D.C., Kirkpatrick B., Marder S.R., Vester-Blokland E., Sun W., Carson W.H., Pikalov A., Assuncao-Talbott S. A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy. J. Clin. Psychiatry 2009, 70(10):1348-1357.
27. Keck P.E., McElroy S.L. Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic. Expert. Opin. Investig. Drugs 2003, 12(4):655-662.
28. Kinon B.J., Gilmore J.A., Liu H., Halbreich U.M. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003, 28(2):S55-S68.
29. Klibanski A., Neer R.M., Beitins I.Z., Ridgway E.C., Zervas N.T., McArthur J.W. Decreased bone density in hyperprolactinemic women. N Engl. J. Med. 1980, 303(26):1511-1514.
30. Knegtering H., van der Moolen A.E., Castelein S., Kluiter H., van den Bosch R.J. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning?. Psychoneuroendocrinology 2003, 28(2):S109-S123.
31. Konarzewska B., Wolczynski S., Szulc A., Galinska B., Poplawska R., Waszkiewicz N. Effect of risperidone and olanzapine on reproductive hormones, psychopathology and sexual functioning in male patients with schizophrenia. Psychoneuroendocrinology 2009, 34(1):129-139.
32. Lee B.H., Kim Y.K., Park S.H. Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30(4):714-717.
33. Lee B.J., Lee S.J., Kim M.K., Lee J.G., Park S.W., Kim G.M., Kim Y.H. Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone. Clin. Psychopharmacol. Neurosci. 2013, 11(2):60-66.
34. Leucht S., Samara M., Heres S., Patel M.X., Furukawa T., Cipriani A., Geddes J., Davis J.M. Dose Equivalents for Second-Generation Antipsychotic Drugs: The Classical Mean Dose Method. Schizophr. Bull. 2015, 41(6):1397-1402.
35. Li X., Tang Y., Wang C. Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PloS One 2013, 8(8):e70179.
36. Lu M.L., Shen W.W., Chen C.H. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32(8):1978-1981.
37. Madhusoodanan S., Parida S., Jimenez C. Hyperprolactinemia associated with psychotropics - a review. Hum. Psychopharmacol. 2010, 25(4):281-297.
38. McCue R.E., Waheed R., Urcuyo L., Orendain G., Joseph M.D., Charles R., Hasan S.M. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br. J. Psychiatry 2006, 189:433-440.
39. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J. Clin. Psychiatry 2005, 66(6):761-767.
40. Paulzen M., Grunder G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int. J. Neuropsychopharmacol. 2007, 10(1):149-151.
41. Peuskens J., Pani L., Detraux J., De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014, 28(5):421-453.
42. Ranjbar F., Sadeghi-Bazargani H., Niari Khams P., Arfaie A., Salari A., Farahbakhsh M. Adjunctive treatment with aripiprazole for risperidone-induced hyperprolactinemia. Neuropsychiatr. Dis. Treat. 2015, 11:549-555.
43. Robinson D.G., Gallego J.A., John M., Petrides G., Hassoun Y., Zhang J.P., Lopez L., Braga R.J., Sevy S.M., Addington J., Kellner C.H., Tohen M., Naraine M., Bennett N., Greenberg J., Lencz T., Correll C.U., Kane J.M., Malhotra A.K. A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr. Bull. 2015, 41(6):1227-1236.
44. Rocha F.L., Hara C., Ramos M.G. Using aripiprazole to attenuate paliperidone-induced hyperprolactinemia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2010, 34(6):1153-1154.
45. Schlosser R., Grunder G., Anghelescu I., Hillert A., Ewald-Grunder S., Hiemke C., Benkert O. Long-term effects of the substituted benzamide derivative amisulpride on baseline and stimulated prolactin levels. Neuropsychobiology 2002, 46(1):33-40.
46. Seeman M.V. Gender differences in the prescribing of antipsychotic drugs. Am. J. Psychiatry 2004, 161(8):1324-1333.
47. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003, 28(8):1400-1411.
48. Smith S., Wheeler M.J., Murray R., O'Keane V. The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis. J. Clin. Psychopharmacol. 2002, 22(2):109-114.
49. Tadori Y., Forbes R.A., McQuade R.D., Kikuchi T. Characterization of aripiprazole partial agonist activity at human dopamine D3 receptors. Eur. J. Pharmacol. 2008, 597(1-3):27-33.
50. Torre D.L., Falorni A. Pharmacological causes of hyperprolactinemia. Ther. Clin. Risk Manag. 2007, 3(5):929-951.
51. Wang Z.M., Xiang Y.T., An F.R., Correll C.U., Ungvari G.S., Wang C.Y., Lai K.Y., Bo Q.J., Li Y., Zhong B.L., Chiu H.F. Frequency of hyperprolactinemia and its associations with demographic and clinical characteristics and antipsychotic medications in psychiatric inpatients in China. Perspect. Psychiatr. Care 2014, 50:257-263.
52. Yasui-Furukori N., Furukori H., Sugawara N., Fujii A., Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J. Clin. Psychopharmacol. 2010, 30(5):596-599.
53. Zhao J., Song X., Ai X., Gu X., Huang G., Li X., Pang L., Ding M., Ding S., Lv L. Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial. PloS One 2015, 10(10):e0139717.